HK 009
Alternative Names: HK-009Latest Information Update: 06 Jun 2022
At a glance
- Originator Hefei HankeMab Biotechnology
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 31 May 2022 Hefei HankeMab Biotechnology has patent protection for HK 009 (Hefei HankeMab Biotechnology website, May 2022)
- 31 May 2022 Early research in Cancer in China (Parenteral) (Hefei HankeMab Biotechnology website, May 2022)